Home » Stocks » ENTX

Entera Bio Ltd. (ENTX)

Stock Price: $1.29 USD 0.05 (4.03%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $1.30 +0.01 (0.78%) Jan 15, 7:56 PM
Market Cap 27.17M
Revenue (ttm) 236,000
Net Income (ttm) -10.80M
Shares Out 12.15M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.29
Previous Close $1.24
Change ($) 0.05
Change (%) 4.03%
Day's Open 1.24
Day's Range 1.22 - 1.32
Day's Volume 638,393
52-Week Range 1.03 - 3.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 days ago

BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Sh...

GlobeNewsWire - 1 month ago

EB613 Phase 2 Placebo-Controlled, Dose-Ranging Study Ongoing in Israel with Complete 3 Month Biomarker Data expected in Q1:21 and Final Bone Mineral Density, or BMD, Data Expected in Q2:21 EB6...

Seeking Alpha - 1 month ago

Entera Bio Ltd. (ENTX) CEO Roger Garceau on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 1 month ago

‒ Completed E nrollment in Phase 2 Clinical Trial of EB613, P ositioned as the F irst P otential O ral B one B uilding P roduct to T reat O steoporosis ‒ ‒ Positive Interim 6-Month Bone Minera...

GlobeNewsWire - 2 months ago

BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report busine...

GlobeNewsWire - 2 months ago

‒ Company Expect s to Report Interim 3 Month Bio m arker Data for All Enrolled Patients in Q1:21 with Final Bone Mineral Density, or BMD, Data Expected in Q2:21 ‒

GlobeNewsWire - 4 months ago

BOSTON and JERUSALEM, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members o...

Seeking Alpha - 4 months ago

Entera Bio Ltd. (ENTX) Interim CEO Roger Garceau on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 months ago

‒ 6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact on  Lumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner – ‒ Company Expects to Complete Patient Enr...

GlobeNewsWire - 5 months ago

BOSTON and JERUSALEM, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report ...

GlobeNewsWire - 5 months ago

BOSTON and JERUSALEM, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its ...

GlobeNewsWire - 5 months ago

BOSTON and JERUSALEM, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of...

GlobeNewsWire - 5 months ago

‒ Approximately 85% of Clinicians Surveyed Likely to Prescribe Oral Parathyroid Hormone (PTH) to Treat Moderate to Severe Osteoporosis ‒

GlobeNewsWire - 6 months ago

‒ Institutional Review Boards (IRBs) Approve Amended Phase 2 Protocol with Newly Enrolled Patients Receiving a 2.5 mg Dose, 1.5 mg Dose, or Placebo ‒

Seeking Alpha - 7 months ago

Entera Bio Ltd.'s (ENTX) CEO Adam Gridley on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 7 months ago

‒ Statistically Significant One Month Increases in P1NP Biomarker  from First 50% of Patients with Highest Dose of EB613 ‒ ‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613...

Seeking Alpha - 9 months ago

Entera Bio Ltd. (ENTX) CEO Adam Gridley on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

BOSTON and JERUSALEM, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today that it inc...

GlobeNewsWire - 1 year ago

BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today it has clos...

Seeking Alpha - 1 year ago

Entera Bio Ltd. (ENTX) CEO Adam Gridley on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today provided a corporate update and reported financial results for the third quarter ended September ...

GlobeNewsWire - 1 year ago

BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan L...

GlobeNewsWire - 1 year ago

JERUSALEM and BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced the presentation of positive results from its pharmacokinetic (PK) and pharmacodynamic...

Seeking Alpha - 1 year ago

Entera Bio Ltd. (ENTX) CEO Adam Gridley on Q2 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

JERUSALEM and BOSTON, Aug. 20, 2019 (GLOBE NEWSWIRE) --  Entera Bio Ltd. (NASDAQ: ENTX) today provided a corporate update and reported financial results for second quarter ended June 30, 2019.

Seeking Alpha - 1 year ago

Entera Bio Ltd. (ENTX) CEO Phillip Schwartz on Q4 2018 Results - Earnings Call Transcript

About ENTX

Entera Bio, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase II clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboratio... [Read more...]

Industry
Biotechnology
IPO Date
Jun 28, 2018
CEO
Adam Gridley
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
ENTX
Full Company Profile

Financial Performance

In 2019, Entera Bio's revenue was $236,000, a decrease of -52.80% compared to the previous year's $500,000. Losses were -$10.80 million, 4.77% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Entera Bio stock is "Buy" and the 12-month stock price forecast is 4.00.

Price Target
$4.00
Analyst Consensus: Buy